1 Prevalence of differences of sex development in Switzerland from 2000-2019

Sara Metzger¹, Grit Sommer^{1,2,3*#}, Christa E. Flück^{1,2*}, on behalf of the Swiss DSD Cohort Study
Group

4 *co-last authors

5

6 ¹ Division of Pediatric Endocrinology, Diabetology and Metabolism, Department of Pediatrics,

7 Inselspital, Bern University Hospital, University of Bern, Switzerland

8 ² Department of Biomedical Research, University of Bern, Switzerland

³ Institute of Social and Preventive Medicine, University of Bern, Switzerland

10

11 Members of the Swiss DSD Cohort Study Group in alphabetical order: Christine Aebi-Ochsner, 12 Private Practice for Paediatric Endocrinology, Biel Switzerland; Kanetee Busiah, Department of 13 Pediatric Endocrinology and Diabetology, CHUV, University Children's Hospital, Lausanne, 14 Switzerland; Mirjam Dirlewanger, Pediatric Endocrine and Diabetes Unit, Children's University 15 Hospital Geneva, Geneva, Switzerland; Sylvia Gschwend, Private Practice for Paediatric 16 Endocrinology, Zug, Switzerland; Melanie Hess, Pediatric Endocrinology and Diabetology, 17 University Children's Hospital Basel, Basel, Switzerland; Beatrice Kuhlmann, Pediatric 18 Endocrinology, Cantonal Hospital Aarau, Aarau, Switzerland and Private Practice for Paediatric 19 Endocrinology, Basel, Switzerland; Dagmar l'Allemand, Department of Endocrinology, 20 Children's Hospital of Eastern Switzerland, St. Gallen, Switzerland; Mariarosaria Lang, 21 Paediatric Endocrinology and Diabetology, University Children's Hospital Zurich, Zurich, 22 Switzerland; Kees Noordam, Centre for Paediatric Endocrinology Zurich (PEZZ), Zurich, 23 Switzerland; Franziska Phan-Hug, Department of Pediatrics, Hospital Morges, Morges and 24 Department of Pediatrics, Hospital Wallis, Sion, Switzerland; Ursina Probst, Department of 25 Pediatrics, Cantonal Hospital Winterthur, Winterthur, Switzerland; Maristella Santi, Department of Pediatrics, Cantonal Hospital Lucerne, Lucerne, Switzerland; Silvia Schmid, Private Practice 26

27	for Paediatric Endocrinology, Dubendorf, Switzerland; Valérie Schwitzgebel, Pediatric Endocrine
28	and Diabetes Unit, Children's University Hospital Geneva, Geneva, Switzerland; Michael
29	Steigert, Department of Pediatrics, Cantonal Hospital Graubuenden, Chur, Switzerland; Gabor
30	Szinnai, Pediatric Endocrinology and Diabetology, University Children's Hospital Basel, Basel,
31	Switzerland; Gerald Theintz, Private Practice for Paediatric Endocrinology, Lausanne,
32	Switzerland.
33	
34	*Correspondence:
35	Grit Sommer
36	Institute of Social and Preventive Medicine
37	Mittelstrasse 43
38	3012 Bern, Switzerland
39	Phone: +4131 684 33 47
40	Email: gritti.sommer@unibe.ch
41	
42	ORCID:
43	Christa Flück 0000-0002-4568-5504
44	Grit Sommer 0000-0002-4205-7932
45	
46	Key words: DSD; intersex; sex chromosome DSD; 46,XY DSD; 46,XX DSD; CAH; gonadal
47	development
48	Disclosure: The authors declare no conflict of interest.

49 **Abstract** (249/250)

50 **Objective:** Reliable data on prevalence of rare differences of sex development (DSD) are

51 lacking. We aimed to estimate population-based prevalence of DSD in Switzerland.

52 **Design:** Retrospective population-based study including individuals with DSD according to

53 Chicago Consensus, born in Switzerland from 2000-2019.

54 Methods: Endocrine care centers in all ten Swiss Children's Hospitals and eight private

55 endocrine practices collected DSD data through the I-DSD registry or case report forms. We

56 calculated prevalence for DSD diagnostic groups and analyzed time trends in prevalence.

57 **Results:** Over the 20-year study period, we identified 561 individuals with DSD. Almost half

58 (n=266, 47%) had sex chromosome DSD, 177 (32%) had 46,XY DSD and 118 (21%) had 46,

59 XX DSD. Causes for 46,XY DSD were disturbed androgen synthesis or action (37/177, 21%),

atypical gonadal development (28/177, 16%), or other causes (112/177, 63%). Causes for

61 46,XX DSD were androgen excess (99/118, 84%), atypical gonadal development (8/118, 7%),

or other causes (11/118, 9%). On average, 28 new cases were born with DSD annually.

63 Prevalence was 17 for sex chromosome DSD, 12 for 46,XY DSD and 8 for 46,XX DSD per

64 100'000 live births and year. One per 7,500 newborn girls had 46,XX congenital adrenal

65 hypoplasia (CAH).

66 **Conclusion:** Prevalence of sex chromosome DSD was lower than expected because of

67 underreporting due to late diagnosis. Prevalence of 46,XX CAH is similar to newborn screening

data, suggesting good completeness of cases. For complex DSD cases, we expect complete

69 coverage. This study provides a valuable resource for policymaking and (inter)national research

70 on DSD.

71 INTRODUCTION

72 Differences of sex development (DSD) is an umbrella term that stands for a heterogeneous 73 group of rare conditions that affect human sex development and maturation (1). The term DSD 74 has first been introduced with the Chicago Consensus Statement in 2006 that defined DSD as 75 "congenital conditions in which the development of chromosomal, gonadal, anatomic sex is 76 atypical" (2). Most DSDs are congenital due to their genetic origins. However, many individuals 77 never receive a genetic diagnosis but are diagnosed as DSD based on their phenotype (3). 78 Although this consensus around terminology has been widely accepted by medical 79 professionals, it remains controversial (4), and other terms have been suggested including 80 intersex, variations of sex development or more recently variations of sex characteristics. New 81 knowledge on human sex development and the introduction of a classification based on 82 genetics clarified the perspective on this broad and complex subject. A clear definition allowed 83 researchers and physicians to identify and work together with persons with DSD and improve 84 efforts towards well-integrated, progressive, patient-centered care and research across the DSD 85 spectrum. The I-DSD Registry is an international database for DSD that allows for standardized 86 and pseudonymized data collection (5). It is a valuable tool for researchers and physicians to 87 record and obtain data of individuals with DSD to solve clinical and translational research 88 questions (5, 6). As of June 2023, this registry included data of 7749 individuals with DSD 89 originating from 135 centers of 45 countries world-wide (7). It has formed the basis of over 65 90 research projects addressing various topics of DSD such as mechanisms of disease of specific 91 subtypes of DSD, genetic and diagnostic approaches, treatment options, long-term outcomes, 92 quality of care and psychosocial topics.

93 Recent developments have shifted perceptions and approaches toward DSD, yet many open 94 research questions remain to improve care for individuals with DSD (1, 8, 9, 10). Provision of 95 optimal healthcare for individuals with DSD and perception by policymakers, ethical and legal 96 bodies as well as society require a clear understanding of the occurrence of these conditions.

97 However, the accurate incidence and prevalence of DSD are still unknown (11). One exception 98 are studies reporting incidences of congenital adrenal hyperplasia (CAH), because CAH is 99 included in national neonatal screening programs (12). Only few studies estimated incidence or 100 prevalence for other types of DSD, but these studies were either old, dating from 1955 to 2000 101 (13), or covered only single centers or regions and thus yielded variable results (14) (15, 16, 17, 102 18, 19, 20, 21, 22, 23). To date, no country has a nation-wide registration system for DSD. 103 Our study is the first to assess prevalence of DSD in a population-based cohort study. We 104 aimed to calculate prevalence and trends in prevalence of DSD diagnostic groups according to

- 105 the Chicago Consensus Classification during the 20-year period from 2000-2019 in Switzerland.
- 106

107 MATERIAL AND METHODS

108 Ethics, Study Design and Participants

For this population-based retrospective observational study cohort, we retrospectively identified
patients with DSD in 19 different Swiss centers of pediatric endocrinology.

111 We included all individuals with DSD as defined by the Chicago Consensus Classification (2),

112 who were born in Switzerland between January 1, 2000 and December 31, 2019. Individuals

113 with DSD were mainly followed by a specialized interdisciplinary team (4) at outpatient clinics of

- pediatric hospitals under the lead of a pediatric endocrinologist. We approached all 11
- departments of pediatric endocrinology in Swiss Children's hospitals to collaborate for data

116 collection, and 10 out of 11 participated covering the whole of Switzerland except the canton of

117 Ticino. We also asked all Swiss pediatric endocrinologists in private practices to report their

118 patients, and 8 followed our call.

119 The Ethics Committee of the Canton of Bern granted ethical approval to the Swiss DSD Cohort

120 Study under BASEC ID 2016-01210. With ethical approval, we were able to collect a core data

121 set without informed consent of participants.

123 Data Collection

124 Participating centers identified eligible patients through patient lists of treating physicians and 125 searches in their administrative clinical databases or hospital coding systems. Physicians 126 extracted data from medical records and filled them into the basic registration module of the I-127 DSD Registry (https://sdmregistries.org/). Centers without access to the registry used a case 128 report form identical to the variables in the I-DSD Registry. Extracted data included treatment 129 center, year of birth, assigned sex at birth, country of birth, karyotype, details of DSD condition 130 including genetic analyses and current gender. We coded each individual according to the 131 diagnostic categories suggested from the Chicago Consensus Classification (2) into three DSD 132 main groups (sex chromosome DSD, 46,XY DSD, 46,XX DSD) and diagnostic subgroups (sex 133 chromosome DSD: Klinefelter syndrome and variant, Turner syndrome and variants, 134 45, X/46, XY and variants, other; 46, XY DSD: disorders of gonadal development, disorders in 135 androgen synthesis or action, other: 46,XY DSD: disorders of gonadal development, androgen 136 excess, other). We clarified missing or inconclusive data with the collaborating physicians. 137 Population-based data on live births came from the Swiss Federal Office of Statistics (SFSO). 138 Numbers of cases of CAH identified by newborn screening came from the Swiss Neonatal 139 Screening laboratory (https://www.neoscreening.ch/de/). 140 To ensure that our cohort did not include duplicate entries of the same individuals with DSD, an 141 independent institution performed record linkage based on first and last name and date of birth.

142

143 Data Analysis and Statistics

We calculated prevalence based on the day the individuals were born, assuming that any DSD regardless of the timing of clinical presentation, is already present at birth, similarly to a Danish study on CAH (24). We calculated prevalence based on population data from the Swiss Federal Statistical Office (SFSO). We calculated the average number of cases born with DSD per year for main DSD categories and specific DSD subgroups during the entire observation period from

149 2000-2019 and for four 5-year intervals (2000-2004, 2005-2009, 2010-2014, 2015-2019). We calculated prevalence of DSD expressed per 100'000 liveborn individuals per year. Depending 150 151 on the diagnosis, we calculated prevalence based on all newborns, or only newborn boys or 152 newborn girls. For all DSDs combined, for the main DSD categories (sex chromosome DSD, 153 46,XY DSD, 46,XX DSD), and for two sex chromosome DSD subgroups (45,X/46,XY and 154 variants, other sex chromosome DSD) we used the number of all newborns. For Klinefelter 155 syndrome and variants and the 46,XY DSD subgroups (disorders of gonadal development, 156 disorders in androgen synthesis or action, other 46,XY DSD) we used newborn boys. For 157 Turner syndrome and variants and the 46,XX DSD subgroups (disorders of gonadal 158 development, androgen excess, other 46,XX DSD) we used newborn girls. We calculated 159 confidence intervals for prevalence using the Poisson distribution (25). We used Stata, Version 160 16.1 for data preparation and descriptive statistics, and R statistic management, R Version 4.2.2 161 for prevalence calculations.

To examine trends in prevalence expressed as annual percentage changes (APC), we used
JoinPoint, Version 4.0.2.2. JoinPoint is a statistical package originally developed by the US
National Cancer Institute to describe trends in cancer incidence and mortality (26). JoinPoint
fitted regression lines through the selected data, with the natural logarithm of proportion
(prevalence) as dependent variable and calendar year (2000-2019) as independent variable.
We allowed for a maximum number of 0 joinpoints to capture overarching trends within the data.

168

169 **RESULTS**

A total of 685 individuals with DSD born between 2000 and 2019 were treated in the 10
pediatric hospitals including all University Children's Hospitals in Switzerland and the 8 private
pediatric practices. We excluded duplicate individuals (n=56) and individuals born outside of
Switzerland or in the canton Ticino (n=66), leading to a final cohort of 561 individuals with DSD
(Figure 1).

175

176

177

178

179 specific diagnoses comprised within these three main DSD categories. 180 181 Prevalence of DSD in Switzerland 182 Throughout the entire 20-year study period spanning from 2000 to 2019, an annual average of 183 76'719 children were born in all Swiss cantons excluding Ticino. During the same period, we 184 identified an average number of 28 individuals with DSD born per year (**Table 2**), resulting in an 185 overall prevalence of 36.6 (95%CI 33.6; 39.7) per 100'000 newborns per year for all DSD 186 diagnoses (Table 2). 187 188 When we stratified our study period into 5-year intervals, annual DSD prevalence per 100'000 189 newborns was highest with 44.3 (95%CI 31.7; 51.7) between 2005-2009, and lowest with 28.2 190 (95%CI 23.4; 33.7) in the most recent interval between 2015-2019 (Figure 2A and Supplemental 191 Table 1). Sex chromosome DSD accounted for the largest proportion of cases among all DSD 192 main groups between 2000-2014. Only between 2015-2019, the 46,XY DSD proportion was 193 larger. Throughout all time intervals, the 46,XX DSD group accounted for the smallest 194 proportion of cases. 195 Sex chromosome DSD prevalence was highest with 24.0 (95%CI 19.2; 29.7) per 100'000 196 newborns per year between 2000-2004 (Figure 2B and Supplemental Table 1). Turner 197 syndrome and variants accounted for the largest proportion of sex chromosome DSD 198 (prevalence 20.0 per 100'000 newborn girls, 95%Cl 16.9;23.5), followed by Klinefelter syndrome 199 and variants (prevalence 9.4 per 100'000 newborn boys, 95%CI 7.4-11.8). Other types of sex 200 chromosome DSD were rare (prevalence 0.5-1.7 per 100'000 newborns). Prevalence of sex

We classified our cohort of 561 individuals into the three main DSD categories according to the

Chicago Consensus Classification (2). A total of 266 (47%) individuals had sex chromosome

DSD, 177 (32%) 46,XY DSD and 118 (21%) 46,XX DSD. Table 1 gives an overview of the

chromosome DSD decreased from 2000-2019 with an APC of -6.3 (95%CI -8.4; -4.1) which was
mainly driven by the Klinefelter syndrome (APC -8.2, 95%CI 11.4; -4.8) and Turner syndrome
group (APC -5.2, 95%CI -7.8; -2.5) (Figures 2B and 3B).

204

205 Prevalence of 46,XY DSD was 11.5 (95%CI 9.9; 13.4) per 100'000 newborns for the entire 206 study period and remained stable over time (APC 1.8, 95%CI -0.5; 4.1) (Table 2, Figure 3C), 207 with a slight trend towards an increasing prevalence after 2014 (Figure 2C). Other 46,XY DSD 208 (prevalence 14.2 per 100'000 newborn boys, 95%CI 11.7; 17.1) was highest among the group 209 of 46,XY DSD, followed by disorders in androgen synthesis or action (prevalence 4.7 per 210 100'000 newborn boys, 95%CI 3.3; 6.5) and disorders of gonadal development (prevalence 3.5 211 per 100'000 newborn boys, 95%CI 2.4; 5.1) (Table 2). While prevalence of other 46,XY DSD 212 increased over time (APC 4.5, 95%CI 1.0-8.1), prevalence of disorders of gonadal development 213 or disorders in androgen synthesis or action remained stable (Figure 3C). 214 215 Prevalence of 46,XX DSD was 7.7 (95%CI 6.4; 9.2) per 100'000 newborns (Table 2, Figures 2D

and 3D), and remained stable over time (APC -2.3, 95%Cl -5.9; 1.4) (Table 2, Figure 3D).

Among 46,XX DSD, the androgen excess group had the highest prevalence with 13.3 (95%CI

218 10.8; 16.2) per 100'000 newborn girls with stable prevalence over the study period. Other types

of 46, XX DSD were rare (prevalence 1.1-1.5 per 100'000 newborn girls).

220

221 Sex registration at birth

In Switzerland sex registration at birth is mandatory and only the traditional categories of either male or female are officially available. We did not observe a difference in ratio of sex registration over the study period (Table 1). In our cohort of 561 individuals, 301 (54%) were registered with female sex at birth and 242 (43%) with male sex at birth. For 18 individuals, physicians reported that sex directly at birth was not assigned (3%; n=14 46,XY and n=4 46,XX), and data on official sex registration at birth was not available to us. All individuals with sex chromosome DSD were
registered with a female or male sex at birth. Discordance between karyotype and sex
registration at birth was found in 28/177 individuals with 46,XY DSD (16%) and in 12/118
individuals with 46,XX DSD (10%). A difference between registered sex at birth and gender at
last follow-up was reported in 5 individuals originally registered female at birth (1%) and in 7
individuals originally registered male at birth (1%) with one individual identifying as both male
and female.

234

235 Where are individuals with DSD cared for?

236 We found that most children and adolescents with DSD in Switzerland (452/561, 80%) were

seen by pediatric endocrinologists working in hospitals with a interdisciplinary DSD team (Figure

4). Pediatric endocrinologists in private practice cared predominantly for children and

adolescents with Turner syndrome, Klinefelter syndrome, or 46,XX androgen excess.

240

241 **DISCUSSION**

242 We report prevalence for different DSD diagnoses according to the Chicago Consensus

243 Classification in a population-based cohort between 2000-2019 in Switzerland. Prevalence of

DSD treated by pediatric endocrinologist was 37 per 100'000 (1:2'735) newborns including sex

chromosome, 46,XY and 46,XX DSD. Overall, DSD prevalence decreased from 2000-2019,

which was driven by a strong decrease in prevalence of sex chromosome DSD. Prevalence of

247 46,XY DSD tended to increase and prevalence of 46,XX DSD to decrease over time.

248

249 Most studies on epidemiology of DSD come from single centers in different countries. These

studies mostly describe prevalence of DSD (15, 18, 20, 21, 27) or atypical genitalia (16, 19, 22),

and only some used the Chicago Consensus Classification. The reported prevalence at birth

ranges from 1:357 when including any kind of atypical genitalia (27) to 1:6'347 when using DSD

diagnoses according to the Chicago Consensus Classification (21). The two existing multicenter
studies from the US (17) and Scotland (23) reported numbers of children with either atypical
genitalia or DSD at birth. The Scottish study registered atypical genitalia in Scotland
prospectively between 2013-2019. They found that in 1 of 1'881 newborns, the treating
physicians suspected a DSD and 1 of 3'318 newborns required DSD specialist consultation
(23).

259 The US study by Finlayson et al (17) compared relative prevalence of DSD diagnoses within a 260 cohort of 99 infants with atypical genitalia to other cohorts and found large differences in relative 261 prevalence of sex chromosome, 46,XY and 46,XX DSD between cohorts. Several factors may 262 contribute to this broad variability, including definition of diagnosis (e.g. inclusion/exclusion of 263 cases without atypical genitalia), differences in study population (e.g. ethnicity, consanguinity), 264 sampling (single center versus multicenter), study design (e.g. prospective, cross-sectional), 265 age of study participants (e.g. newborns, children, all ages). Thus population-based data to 266 obtain representative estimates of prevalence for different DSD diagnoses is crucial.

267

268 Sex chromosome DSD

269 We calculated prevalence of DSD based on live birth rates in Switzerland. Our overall 270 prevalences are lower than published data for sex chromosome DSD (28, 29). Turner syndrome 271 occurs in 25-50 individuals per 100'000 females (28, 30). We found a prevalence of 24-29 per 272 100'000 newborn girls for Turner syndrome and variants during 2000-2009, which decreased to 273 9 per 100'000 during 2015-2019. This decrease in prevalence over time is due to the fact that 274 less than one third of individuals with Turner syndrome are diagnosed in childhood or 275 adolescence (28, 30). The reported prevalence for Klinefelter syndrome varies from 40-250 per 276 100'000 males with the main proportion only diagnosed in adulthood (31, 32). For Klinefelter 277 and variants we found a prevalence of 18 per 100'000 newborn boys during 2000-2004 that 278 decreased to 5 per 100'000 during 2015-2009. Our cohort included individuals with DSD who

were born from 2000-2019, thus a large proportion of individuals were too young to have
received a Turner syndrome or Klinefelter syndrome diagnosis. Cohort studies with systematic
screening or longer observation periods are needed to capture real prevalence estimates for
individuals with Turner and Klinefelter syndrome. Some individuals with Turner or Klinefelter
syndrome may not have required pediatric endocrine care and thus were missed by our cohort
study.

285

286 Non-chromosomal DSD

We assume almost complete coverage of rare and complex subgroups of non-chromosomal DSD with atypical genitalia. These individuals are often diagnosed at birth and require extensive diagnostic assessments which leads to treatment by specialized DSD teams. Specialized DSD physicians reported all their DSD cases to our study cohort, reducing the likelihood of missing eligible individuals. Comparable prevalence data is scarce for individuals with complex forms of DSD.

293

294 46,XY DSD comprise disorders of gonadal development, disorders in androgen synthesis or 295 action, and other forms. A Swedish study (33) found a prevalence of 6.4 per 100'000 live born 296 females for individuals with a 46,XY karyotype and a female phenotype. These figures are hard 297 to compare to our results, because we calculated prevalence based on newborn boys and did 298 not include data on phenotype. We observed a prevalence of 3.5 per 100'000 newborn boys for 299 individuals with disorders of gonadal development and of 4.7 for individuals with androgen 300 synthesis or action. The largest group among the 46,XY DSD was the heterogeneous group of 301 other 46,XY DSD including complex genital and cloacal anomalies. Often individuals of this 302 group are not classified as DSD in hospital administration coding systems, as they have their 303 first presentation in departments other than endocrinology (e.g. urology). Only a fraction is 304 referred to specialized DSD teams for interdisciplinary care and genetic work-up. Genetic work-

305 up does not yield a genetic diagnosis relating to a DSD in >50% of individuals (34). In a US 306 single center study among 131 boys with proximal hypospadias, only 60 (46%) received 307 endocrine and genetic testing and 9 (7%) received a DSD diagnosis (35). In a Chinese single 308 center study in 165 individuals with proximal hypospadias, only 14 (8%) obtained a DSD 309 diagnosis (36). Depending on which forms of hypospadias might qualify as DSD, we assume 310 that we have largely underestimated the prevalence of the subgroup of other 46,XY DSD in our 311 study. Interestingly, we observed the highest prevalence in the most recent study period from 312 2015-2019. Increased awareness of DSD among different specialties may have led to more 313 referrals to pediatric endocrinologists in more recent years, particularly after the Chicago 314 Consensus Statement. This group may also include individuals who have not yet received a 315 genetic DSD diagnosis that would allow categorization into the more specific DSD 316 subcategories.

317

318 46,XX DSD comprise disorders of gonadal development, androgen excess and other forms. 319 Most studies describe prevalence for individuals with androgen excess, mostly for CAH. Only 320 one nation-wide cohort study from Sweden reported data on other forms of 46,XX DSD (33). 321 They report a prevalence of 3.5-4.7 per 100'000 newborn males for individuals with a 46,XX 322 karyotype and a male phenotype who mainly presented for fertility concerns and were 323 diagnosed with DSD. Among their study cohort of 44 individuals, 33 had disorders of gonadal 324 development and 3 had CAH. Comparison to our data is difficult, because categorization of 325 46,XX DSD diagnoses differed. In our study, we calculated prevalence for 46,XX DSD based on 326 newborn girls while they used newborn boys, and we did not collect data on phenotype. 327 Because our cohort was relatively young, we may have missed individuals with 46,XX DSD who 328 only come to medical attention later in life due to fertility concerns, leading to an 329 underestimation of the prevalence in this DSD group. We also assume underreporting of 46,XX 330 disorders of gonadal development and other 46,XX DSD for the earliest interval from 2000-2004

331 due to the retrospective study design and lack of consensus on diagnostic nomenclature. Several countries, including Switzerland, published CAH prevalence data from their national 332 333 neonatal screening programs. Our prevalence estimates are hard to compare to data from the 334 Swiss Newborn Screening (https://www.neoscreening.ch/de), because they do not distinguish 335 between girls and boys and they only capture individuals with classic CAH. Our cohort included 336 individuals with non-classic CAH. Prevalence of all subtypes of CAH in Danish females was 337 15.1 per 100'000 newborn girls (24), which was comparable to our study with a prevalence of 338 13.3 per 100'000 newborn girls for 46,XX androgen excess.

339

340 The limitations of available data illustrate the need for national or international registries for rare 341 DSD covering the entire population to enable incidence and prevalence estimates based on the 342 population at risk. Real world numbers are important for discussing controversial topics and 343 receiving the necessary attention and resources from the community to obtain the best possible 344 support for individuals with DSD (8, 23). This concerns political, legal and medical affairs as well 345 as research activities and has been recognized by official bodies in several countries worldwide. 346 The Swiss National Advisory Commission on Biomedical Ethics (37) and the Swiss Academy of 347 Medical Sciences have published recommendations in 2012 and 2016 which include the 348 establishment of population-based registration of DSD. According to international 349 recommendations, individuals with DSD should be cared for by interdisciplinary DSD teams at 350 qualified centers (1, 4, 8, 10, 38, 39, 40, 41). In Switzerland, most persons with DSD born 351 between 2000 and 2019 and followed by a pediatric endocrinologist are cared for in a hospital 352 setting where interdisciplinary DSD teams are established or with a connection to a DSD team. 353

Sex registration at birth, sex reassignment and gender in later life are topics which are often
discussed controversially by policy makers, medical professionals, patient representatives and
human rights activists because many questions are unsolved. One of the most controversially

discussed question is whether medical treatments should be offered to children with atypical
genitalia who cannot consent or whether it should be banned by a legal embargo (4, 9).
Accurate estimations regarding the number of affected individuals and families, supported by
data are lacking, but would help in the discourse. Our study showed that Swiss DSD teams treat
only few individuals with rare forms of DSD for which state-of-the-art workup does not reveal a
clear diagnosis and treatment plan (1, 10).

363 In a multicenter study from Scotland including individuals with atypical genitalia at birth, sex 364 registration was only delayed in 1 of 11'097 newborns who had atypical genitalia at birth 365 suggesting a complex form of DSD requiring extensive diagnostic procedures. In all individuals 366 sex was registered within the first 2 weeks of life, and in only one individual, sex was reassigned 367 in the first 3 months of life (23). In our 20-year study period, only 13/543 individuals (2.4 %) had 368 a gender at last follow-up that differed to the registered sex at birth. This may indicate that sex 369 registration at birth is mostly fitting. However, data on sex registration was not available in 18 370 individuals (3.2 %) and we did not record age at last follow up. In addition, our study cohort was 371 young and gender incongruence might manifest only later in life. Thus, we may have slightly 372 underestimated the frequency of gender reassignment in DSD.

373

374 Only population-based data collections with complete prospective and standardized follow-up 375 can yield reliable estimates on DSD prevalence, gender reassignment, and other topics such as 376 treatment satisfaction. To solve open questions on frequencies of hormonal and surgical 377 treatments in individuals with DSD and whether these treatments align with international 378 recommendations, data registries need to be tailored and standardized for different DSD 379 diagnoses. The I-DSD Registry is a rare disease registry which allowed to answer many open 380 questions in the past (5) and proved to be a valuable tool for our study. It offers additional value 381 for physicians and researchers to join international studies on specific diagnosis groups. 382 Particularly in the field of rare diseases, international networking is very important.

383 This is the first population-based study reporting on overall DSD prevalence and prevalence of 384 subcategories as defined by the Chicago Consensus Classification. Our study, however, is 385 limited by underestimation of prevalence for individuals with DSD. Our time interval of data 386 collection was relatively short and very recent (from 2000-2019), leading to a young study 387 population at time of data collection. Thus, our study did not capture individuals with DSD who 388 have not yet received a diagnosis. Identification of individuals with DSD was retrospective, thus 389 we may have missed patients which were not correctly coded as DSD in the administrative 390 clinical databases or hospital coding systems. Our data collection covered the whole of 391 Switzerland except for the canton of Ticino. Ticino is a geographically distinct region in the 392 South of Switzerland, and the only canton where Italian is the official language. It is thus unlikely 393 that individuals with DSD born and living in Ticino are treated in other cantons. As the Chicago 394 Consensus Classification was published and implemented in 2006, and the structure of the I-395 DSD Registry changed during our study period, classification of DSD might have differed over 396 time. To avoid misclassification, a designated study team coded all DSD cases into categories 397 according to the Chicago Consensus Classification based on extracted data. We could not 398 calculate incidence of DSD, because information on year of diagnosis was missing. We also 399 could not calculate the external genitalia score (EGS) (42) or the external masculinization score 400 (EMS) (43), because the core data set used in this study did not include phenotype information. 401 However, the scope of our study focused on prevalence of DSD according to Chicago 402 Consensus Classification, and we did not require phenotype information for coding.

403

In summary, we found that individuals with complex forms of DSD were rare and received
treatment from interdisciplinary specialized DSD teams. Our data, similar to other studies,
underestimated prevalence. Systematic prospective data collection is needed to provide robust
estimates on DSD occurrence. Standard guidelines for analyzing prevalence of DSD are lacking
to enable comparison of countries and studies. Such guidelines should include standards on

409 classification of diagnostic groups and a definition of the population at risk for each DSD410 diagnostic subgroup.

411

412 Funding

This work was supported by the Swiss Society of Endocrinology and Diabetology (SGED), by
the Boveri Foundation Zürich and by the "Stiftung Kinderinsel".

415

416 Acknowledgements

417 We thank the Swiss DSD Cohort Study Group for their support. Members of this groups who 418 helped in the collection of data are (in alphabetical order): Christine Aebi-Ochsner, Private 419 Practice for Paediatric Endocrinology, Biel Switzerland; Kanetee Busiah, Department of 420 Pediatric Endocrinology and Diabetology, CHUV, University Children's Hospital, Lausanne, 421 Switzerland: Mirjam Dirlewanger, Pediatric Endocrine and Diabetes Unit, Children's University 422 Hospital Geneva, Geneva, Switzerland; Sylvia Gschwend, Private Practice for Paediatric 423 Endocrinology, Zug, Switzerland; Melanie Hess, Pediatric Endocrinology and Diabetology, 424 University Children's Hospital Basel, Basel, Switzerland; Beatrice Kuhlmann, Pediatric 425 Endocrinology, Cantonal Hospital Aarau, Aarau, Switzerland and Private Practice for Paediatric 426 Endocrinology, Basel, Switzerland; Dagmar l'Allemand, Department of Endocrinology, 427 Children's Hospital of Eastern Switzerland, St. Gallen, Switzerland; Mariarosaria Lang, 428 Paediatric Endocrinology and Diabetology, University Children's Hospital Zurich, Zurich, 429 Switzerland; Kees Noordam, Centre for Paediatric Endocrinology Zurich (PEZZ), Zurich, 430 Switzerland; Franziska Phan-Hug, Department of Pediatrics, Hospital Morges, Morges and 431 Department of Pediatrics, Hospital Wallis, Sion, Switzerland; Ursina Probst, Department of 432 Pediatrics, Cantonal Hospital Winterthur, Winterthur, Switzerland; Maristella Santi, Department 433 of Pediatrics, Cantonal Hospital Lucerne, Lucerne, Switzerland; Silvia Schmid, Private Practice 434 for Paediatric Endocrinology, Dubendorf, Switzerland; Valérie Schwitzgebel, Pediatric Endocrine 17

435	and Diabetes Unit, Children's University Hospital Geneva, Geneva, Switzerland; Michael
436	Steigert, Department of Pediatrics, Cantonal Hospital Graubuenden, Chur, Switzerland; Gabor
437	Szinnai, Pediatric Endocrinology and Diabetology, University Children's Hospital Basel, Basel,
438	Switzerland; Gerald Theintz, Private Practice for Paediatric Endocrinology, Lausanne,
439	Switzerland.
440	
441	Data Availability Statement
442	Data of this study are registered in the I-DSD Registry and can be accessed upon request. I-
443	DSD governance and rules apply, see https://sdmregistries.org/.
444	
445	Tables
446	Table 1: Numbers and proportions of DSD cases in Switzerland born between 2000 and 2019,
447	by sex at birth.
448	Table 2. Prevalence, average number of cases per year of children identified with DSD in
449	Switzerland, born between 2000-2019, by diagnostic group.
450	
451	Figure Legends
452	Figure 1: Patient recruitment and exclusion flow chart.
453	Figure 2: Comparison of prevalence of identified DSDs in Switzerland between 2000-2004,
454	2005-2009, 2010-2014 and 2015-2019, by DSD diagnostic group, according to the Chicago
455	consensus classification of DSD. Error bars indicate 95% confidence intervals. Abbreviations:
456	DSD, Differences of Sex Development
457	Figure 3: Trends in prevalence of identified DSDs in Switzerland between 2000-2019, by DSD
458	diagnostic group according to the Chicago consensus classification of DSD. Abbreviations:
459	DSD, Differences of Sex Development

- 460 **Figure 4:** Number of DSD diagnoses according to the Chicago consensus classification by type
- 461 of treatment center, identified in Switzerland between 2000-2019.
- 462 Abbreviations: DSD, Differences of Sex Development
- 463
- 464 Supplemental material
- 465 **Supplemental Table 1:** Prevalence, average number of cases per year and sex ratio of
- 466 children identified with DSD in Switzerland, born between 2000-2019, by diagnostic group and
- 467 5-year periods.
- 468
- 469
- 470
- 471
- 472 References

Cools M, Nordenstrom A, Robeva R, Hall J, Westerveld P, Fluck C, et al. Caring for
 individuals with a difference of sex development (DSD): a Consensus Statement. Nat Rev
 Endocrinol. 2018;14(7):415-29.

476 2. Hughes IA, Houk C, Ahmed SF, Lee PA, Lawson Wilkins Pediatric Endocrine

477 Society/European Society for Paediatric Endocrinology Consensus G. Consensus statement on 478 management of intersex disorders. J Pediatr Urol. 2006;2(3):148-62.

Fluck CE, Guran T. Ambiguous Genitalia in the Newborn. In: Feingold KR, Anawalt B,
Blackman MR, Boyce A, Chrousos G, Corpas E, et al., editors. Endotext. South Dartmouth
(MA)2000.

482 4. Lee PA, Nordenstrom A, Houk CP, Ahmed SF, Auchus R, Baratz A, et al. Global

- 483 Disorders of Sex Development Update since 2006: Perceptions, Approach and Care. Horm Res
 484 Paediatr. 2016;85(3):158-80.
- 485 5. Lucas-Herald AK, Ali SR, McMillan C, Rodie ME, McMillan M, Bryce J, et al. I-DSD: The
 486 First 10 Years. Horm Res Paediatr. 2023;96(2):238-46.
- 487 6. Ali SR, Lucas-Herald A, Bryce J, Ahmed SF. The Role of International Databases in
 488 Understanding the Aetiology and Consequences of Differences/Disorders of Sex Development.
 489 Int J Mol Sci. 2019;20(18).
- Ahmed SF. The I-DSD/I-CAH/I-TS Network Activity Report 2023 2023 [Available from:
 chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/<u>https://sdmregistries.org/wp-</u>
- 492 <u>content/uploads/2023/08/I-DSD-Activity-Report-June-2023-v2-27.7.23.pdf</u>.
 493 8. Hiort O, Cools M, Springer A, McElreavey K, Greenfield A, Wudy SA, et al. Addressing
- 495 a. Flort O, Cools M, Springer A, McElleavey K, Greenheid A, Wudy SA, et al. Addressing 494 gaps in care of people with conditions affecting sex development and maturation. Nat Rev

494 gaps in care of people with conditions affecting sex development and maturation. Nat 495 Endocrinol. 2019;15(10):615-22.

- 496 9. Cools M, Simmonds M, Elford S, Gorter J, Ahmed SF, D'Alberton F, et al. Response to
 497 the Council of Europe Human Rights Commissioner's Issue Paper on Human Rights and
 498 Intersex People. Eur Urol. 2016;70(3):407-9.
- Fluck C, Nordenstrom A, Ahmed SF, Ali SR, Berra M, Hall J, et al. Standardised data
 collection for clinical follow-up and assessment of outcomes in differences of sex development
 (DSD): recommendations from the COST action DSDnet. Eur J Endocrinol. 2019;181(5):545-64.
 Sax L. How common is intersex? a response to Anne Fausto-Sterling. J Sex Res.
 2002;39(3):174-8.
- 12. Claahsen-van der Grinten HL, Speiser PW, Ahmed SF, Arlt W, Auchus RJ, Falhammar
 H, et al. Congenital Adrenal Hyperplasia-Current Insights in Pathophysiology, Diagnostics, and
 Management. Endocr Rev. 2022;43(1):91-159.
- 507 13. Blackless M, Charuvastra A, Derryck A, Fausto-Sterling A, Lauzanne K, Lee E. How 508 sexually dimorphic are we? Review and synthesis. Am J Hum Biol. 2000;12(2):151-66.
- 509 14. Conway GS. Differences in Sex Development (DSD) and related conditions:
- 510 mechanisms, prevalences and changing practice. Int J Impot Res. 2023;35(1):46-50.
- 511 15. Ata A, Ozen S, Onay H, Uzun S, Goksen D, Ozkinay F, et al. A large cohort of disorders
 512 of sex development and their genetic characteristics: 6 novel mutations in known genes. Eur J
 513 Med Genet. 2021;64(3):104154.
- 514 16. De Paula GB, Barros BA, Carpini S, Tincani BJ, Mazzola TN, Sanches Guaragna M, et
 515 al. 408 Cases of Genital Ambiguity Followed by Single Multidisciplinary Team during 23 Years:
 516 Etiologic Diagnosis and Sex of Rearing. Int J Endocrinol. 2016;2016:4963574.
- 517 17. Finlayson C, Rosoklija I, Aston CE, Austin P, Bakula D, Baskin L, et al. Baseline
- 518 Characteristics of Infants With Atypical Genital Development: Phenotypes, Diagnoses, and Sex 519 of Rearing. J Endocr Soc. 2019;3(1):264-72.
- 520 18. Ganie Y, Aldous C, Balakrishna Y, Wiersma R. Disorders of sex development in children
 521 in KwaZulu-Natal Durban South Africa: 20-year experience in a tertiary centre. J Pediatr
 522 Endocrinol Metab. 2017;30(1):11-8.
- Heeley JM, Hollander AS, Austin PF, Merritt DF, Wesevich VG, Washington University
 School of Medicine in St Louis DSDT, et al. Risk association of congenital anomalies in patients
 with ambiguous genitalia: A 22-year single-center experience. J Pediatr Urol. 2018;14(2):153
 e1- e7.
- 527 20. Juniarto AZ, van der Zwan YG, Santosa A, Ariani MD, Eggers S, Hersmus R, et al.
 528 Hormonal evaluation in relation to phenotype and genotype in 286 patients with a disorder of
 529 sex development from Indonesia. Clin Endocrinol (Oxf). 2016;85(2):247-57.
- 530 21. Man E, Mushtaq I, Barnicoat A, Carmichael P, Hughes CR, Davies K, et al. A Single-531 Center, Observational Study of 607 Children and Young People Presenting With Differences of 532 Sex Development (DSD). J Endocr Soc. 2022;7(1):bvac165.
- 533 22. Manzoor J, Aftab S, Yaqoob M. Ambiguous genitalia: An overview of 7 years experience 534 at the Children's Hospital & Institute of Child Health, Lahore, Pakistan. Pak J Med Sci. 535 2010:25(1):151.5
- 535 2019;35(1):151-5.
- Sign 23. Rodie ME, Ali SR, Jayasena A, Alenazi NR, McMillan M, Cox K, et al. A Nationwide
 Study of the Prevalence and Initial Management of Atypical Genitalia in the Newborn in
 Scotland. Sex Dev. 2022;16(1):11-8.
- 539 24. Berglund A, Ornstrup MJ, Lind-Holst M, Duno M, Baekvad-Hansen M, Juul A, et al.
- 540 Epidemiology and diagnostic trends of congenital adrenal hyperplasia in Denmark: a
- retrospective, population-based study. Lancet Reg Health Eur. 2023;28:100598.
- 542 25. Begaud B, Martin K, Abouelfath A, Tubert-Bitter P, Moore N, Moride Y. An easy to use
- 543 method to approximate Poisson confidence limits. Eur J Epidemiol. 2005;20(3):213-6.
- 544 26. Kim HJ, Chen HS, Byrne J, Wheeler B, Feuer EJ. Twenty years since Joinpoint 1.0: Two 545 major enhancements, their justification, and impact. Stat Med. 2022;41(16):3102-30.

546 27. Ameyaw E, Asafo-Agyei SB, Hughes IA, Zacharin M, Chanoine JP. Incidence of 547 disorders of sexual development in neonates in Ghana: prospective study. Arch Dis Child. 548 2019;104(7):636-8. 549 28. Gravholt CH, Andersen NH, Conway GS, Dekkers OM, Geffner ME, Klein KO, et al. 550 Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting. Eur J Endocrinol. 551 552 2017;177(3):G1-G70.

- Zitzmann M, Aksglaede L, Corona G, Isidori AM, Juul A, T'Sjoen G, et al. European
 academy of andrology guidelines on Klinefelter Syndrome Endorsing Organization: European
 Society of Endocrinology. Andrology. 2021;9(1):145-67.
- Stochholm K, Juul S, Juel K, Naeraa RW, Gravholt CH. Prevalence, incidence,
 diagnostic delay, and mortality in Turner syndrome. J Clin Endocrinol Metab. 2006;91(10):3897902.
- 559 31. Herlihy AS, Halliday JL, Cock ML, McLachlan RI. The prevalence and diagnosis rates of 560 Klinefelter syndrome: an Australian comparison. Med J Aust. 2011;194(1):24-8.
- 561 32. Bojesen A, Juul S, Gravholt CH. Prenatal and postnatal prevalence of Klinefelter 562 syndrome: a national registry study. J Clin Endocrinol Metab. 2003;88(2):622-6.
- 563 33. Berglund A, Johannsen TH, Stochholm K, Viuff MH, Fedder J, Main KM, et al. Incidence,
- 564 Prevalence, Diagnostic Delay, and Clinical Presentation of Female 46,XY Disorders of Sex
 565 Development. J Clin Endocrinol Metab. 2016;101(12):4532-40.
- Audi L, Ahmed SF, Krone N, Cools M, McElreavey K, Holterhus PM, et al. GENETICS IN
 ENDOCRINOLOGY: Approaches to molecular genetic diagnosis in the management of
 differences/disorders of sex development (DSD): position paper of EU COST Action BM 1303
 DODredit Functional 2010;170(4):D107, D000
- 569 'DSDnet'. Eur J Endocrinol. 2018;179(4):R197-R206.
- 35. Johnson EK, Jacobson DL, Finlayson C, Yerkes EB, Goetsch AL, Leeth EA, et al.
 Proximal Hypospadias-Isolated Genital Condition or Marker of More? J Urol. 2020;204(2):34552.
- 573 36. Wong YS, Tam YH, Pang KKY, Yau HC. Incidence and diagnoses of disorders of sex 574 development in proximal hypospadias. J Pediatr Surg. 2018;53(12):2498-501.
- 575 37. Ethics SNACoB. Variations of sex development. Bern, Switzerland: SAMW; 2012.
- 576 38. Lucas-Herald AK, Rodie ME, Ahmed SF. Update on the management of a newborn with 577 a suspected difference of sex development. Arch Dis Child. 2021.
- 578 39. Lucas-Herald AK, Scougall K, Ahmed SF. Delivery of multidisciplinary care in the field of 579 differences and disorders of sex development (DSD). Expert Rev Endocrinol Metab. 580 2022;17(3):225-34.
- 40. Wisniewski AB, Batista RL, Costa EMF, Finlayson C, Sircili MHP, Denes FT, et al.
- 582 Management of 46,XY Differences/Disorders of Sex Development (DSD) Throughout Life. 583 Endocr Rev. 2019;40(6):1547-72.
- 41. Bever YV, Bruggenwirth HT, Wolffenbuttel KP, Dessens AB, Groenenberg IAL, Knapen
- 585 M, et al. Under-reported aspects of diagnosis and treatment addressed in the Dutch-Flemish 586 guideline for comprehensive diagnostics in disorders/differences of sex development. J Med 587 Genet. 2020;57(9):581-9.
- 588 42. van der Straaten S, Springer A, Zecic A, Hebenstreit D, Tonnhofer U, Gawlik A, et al.
- 589 The External Genitalia Score (EGS): A European Multicenter Validation Study. J Clin Endocrinol 590 Metab. 2020;105(3).
- 43. Ahmed SF, Khwaja O, Hughes IA. The role of a clinical score in the assessment of ambiguous genitalia. BJU Int. 2000;85(1):120-4.

Table 1: Numbers and proportions of DSD cases in Switzerland born between 2000 and 2019, by sex at birth

				Sex at birth					
	То	otal Female		Male		Other/ Not			
	N=	561	N=	301	N=242		N=18		
	n	%	n	%	n	%	n	%	
Period of birth									
2000-2004	146	26	83	28	61	25	2	11	
2005-2009	160	28	92	31	60	25	8	44	
2010-2014	136	24	78	26	54	22	4	22	
2015-2019	119	21	48	16	67	28	4	22	
Sex chromosome DSD	266	100	171	100	95	100	0	n/a	
Klinefelter syndrome and variants	74	28	0	0	74	78	0	n/a	
Turner syndrome and variants	149	56	148	87	1	1	0	n/a	
45.X/46.XY and variants	33	12	22	13	11	12	0	n/a	
Other	10	4	1	1	9	9	0	n/a	
46 XY DSD	177	100	28	100	135	100	14	100	
Disorders of gonadal development	28	16	9	32	17	13	2	14	
Complete or partial gonadal dysgenesis	16	10	8	02	7	10	1	• •	
Gonadal regression	q		0		a a		0		
Ovotesticular DSD	3		1		1		1		
Disorders in androgen synthesis or action	37	21	18	64	18	13	1	7	
Disorders in androgen synthesis of action	12	21	2	04	0	10	1	'	
Disorders of androgen action	10		2 16		3		0		
Disorders of AMH or AMH receptor	19		0		5		0		
	110	60	1	4	100	74	11	70	
	112	03	1	4	100	74	10	79	
	100		1		95		10		
	2		0		1		1		
Other	4		0		4		0		
46,XX DSD	118	100	102	100	12	100	4	100	
Disorders of gonadal development	8	7	2	2	6	50	0	0	
Gonadal dysgenesis	2		2		0		0		
Ovotesticular DSD	2		0		2		0		
Testicular DSD	4		0		4		0		
Androgen excess	99	84	89	87	6	50	4	100	
Fetal	97		87		6		4		
Fetoplacental	2		2		0		0		
Maternal	0		0		0		0		
Other	11	9	11	11	0	0	0	0	
Cloacal anomalies	7		7		0		0		
Other	4		4		0		0		
Gender at last follow-up									
Female	304	54	294	52	5	1	5	1	
Male	256	46	6	1	237	42	13	2	
Both	1	0.2	1	0.2	0	0	0	0	

Abbreviations: AMH, Anti-Mullerian hormone; DSD, differences of sex development; n/a, not applicable.

Table 2

Prevalence, average number of cases per year of individuals identified with DSD in Switzerland, born between 2000-2019, by diagnostic group.

	Average number of cases/year	Prevalence per 100.000 newborns per year (95% CI)	1:N newborns
All DSD diagnoses ^a	28.1	36.6 (33.6; 39.7)	2735
DSD diagnostic group			
Sex chromosome DSD ^a	13.3	17.3 (15.3; 19.5)	5768
46,XY DSD ^a	8.9	11.5 (9.9; 13.4)	8669
46,XX DSD ^a	5.9	7.7 (6.4; 9.2)	13003
Sex chromosome DSD			
Klinefelter syndrome and variants ^b	3.7	9.4 (7.4; 11.8)	10660
Turner syndrome and variants ^c	7.5	20.0 (16.9; 23.5)	5004
45,X/46,XY and variants ^a	1.7	2.2 (1.5; 3.0)	46496
Other ^a	0.5	0.7 (0.3; 1.2)	153437
46,XY DSD			
Disorders of gonadal development ^b	1.4	3.5 (2.4; 5.1)	28172
Disorders in androgen synthesis or action ^b	1.9	4.7 (3.3; 6.5)	21319
Other ^b	5.6	14.2 (11.7; 17.1)	7043
46,XX DSD			
Disorders of gonadal development ^c	0.4	1.1 (0.5; 2.1)	93195
Androgen excess ^c	5.0	13.3 (10.8; 16.2)	7531
Other ^c	0.6	1.5 (0.7; 2.6)	67778

Abbreviations: CI, confidence interval; DSD, differences of sex development.

Footnotes:

^aPrevalence calculated based on newborns of both sexes.

^bPrevalence calculated based on newborn boys. ^cPrevalence calculated based on newborn girls.



Figure 1: Identification of the Swiss DSD cohort. Study participants were identified through pediatric endocrinology departments in pediatric hospitals and private practices specialized in endocrine care.

A DSD diagnostic main groups



B Sex chromosome DSD



*Prevalence calculated per 100.000 newborns of both sexes except for Klinefelter syndrome and variants (per 100.000 newborn boys) and for Turner syndrome and variants (per 100.000 newborn girls).

C 46,XY DSD





Figure 2: Comparison of prevalence of identified individuals with DSD in Switzerland between 2000-2004, 2005-2009, 2010-2014 and 2015-2019, by DSD diagnostic group, according to the Chicago Consensus Classification. Error bars indicate 95% confidence intervals. Abbreviations: DSD, differences of sex development.





B Sex chromosome DSD



*Prevalence calculated per 100.000 newborns of both sexes except for Klinefelter syndrome and variants (per 100.000 newborn boys) and for Turner syndrome and variants (per 100.000 newborn girls).

C 46,XY DSDs

D 46,XX DSDs



Figure 3: Trends in prevalence of identified DSDs in Switzerland between 2000-2019, by DSD diagnostic group according to the Chicago Consensus Classification. We used JoinPoint regression to analyze the annual percentage change (APC) in prevalence over time. We did not model APC in diagnostic groups where there were no cases in >3 calendar years. Bold letters indicate p-values <0.5. Abbreviations: APC, Annual Percent Change; DSD, differences of sex development.



Figure 4: Number of individuals with DSD according to the Chicago Consensus Classification by type of treatment center, identified in Switzerland between 2000-2019. Abbreviations: DSD, differences of sex development.